Phase 1a Study Will Assess Novel Checkpoint Inhibitor as a Single Agent in Solid Tumors
REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, announced today that the first patient has been dosed in the company's Phase 1a clinical trial of anti-TIGIT (OMP-313M32). Anti-TIGIT is an investigational immuno-oncology therapeutic candidate intended to block suppression of the immune system in tumors and enable immune system anti-tumor activity, similar to marketed checkpoint inhibitors that target the PD-L1-PD-1 axis.
"The first wave of immuno-oncology agents demonstrated that disabling immune suppression mechanisms in tumors can enable the body's immune system to fight cancers with good efficacy. Still, available immunotherapies have limited results for many cancer patients, and there remains a pressing need for new agents and combinations to improve outcomes," said Johanna Bendell, M.D., Associate Director of the Drug Development Program at Sarah Cannon Research Institute and a lead investigator for the Phase 1a anti-TIGIT study. "The immuno-suppressive receptor TIGIT is expressed on many different tumor types, giving us reason to believe that an anti-TIGIT antibody, such as OncoMed's OMP-313M32, has potential for broad activity in cancer patients. I look forward to seeing its performance in the clinic."
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1024817